Engflag

Avil 1,25%

Quick links to important sections

Avil 1,25%

Avil 1,25%_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avil 1,25%

Property Description
Active ingredient Pheniramine maleate
Form Aqueous Solution (1.25%)
Pharmacological class First-Generation Antihistamine
Common use (General) Management of acute systemic allergic symptoms
Origin Synthetic Alkylamine derivative
Brand Note Typically manufactured by Sanofi or its regional affiliates

What Type of Medicine is Avil 1,25%?

Avil 1,25% is a pharmaceutical preparation containing the active compound Pheniramine maleate, which is formally classified as a first-generation antihistamine and functions as a Histamine H1-receptor antagonist. This compound is chemically defined as a substituted alkylamine, placing it within the category of synthetic organic compounds. In this capacity, its primary function is to block the effects of histamine.

Composition and Form of the Pheniramine Maleate Solution

The specific product, Avil 1,25%, is formulated as a sterile single-ingredient aqueous solution where Pheniramine maleate is integrated at a concentration of 1.25% (weight per volume). This unique liquid presentation is designed primarily for parenteral delivery, which involves administering the medication systemically, bypassing the digestive tract. The solution form is engineered to provide a rapid and controlled dose of Pheniramine maleate, distinguishing it from slower-acting oral preparations.

General Purpose and Antiallergic Function

The general purpose of Avil 1,25% is to serve as an antiallergic agent by directly interrupting the biological cascade initiated by histamine. Its mechanism involves competitive antagonism at the H1-receptors, which prevents the binding of histamine—a key mediator in hypersensitivity responses—to its target sites. This mechanism counters the source of systemic allergic manifestations. The medicine’s role is to neutralize the inflammatory effects caused by the body’s allergic reaction.

What side effects are possible with Avil 1,25%?

Possible Side Effects and Safety Information

The safety profile for Avil 1,25% (Pheniramine maleate) is formally defined by effects common to first-generation antihistamines, documented in regulatory product information. Adverse reactions are classified by frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

The most commonly documented effects in regulatory labeling are related to the central nervous system (CNS):

Classification Examples of Reactions
Very Common (ge 1/10) Sedation, Somnolence (drowsiness)
Common (ge 1/100 to < 1/10) Headache, Dizziness, Disturbance in attention, Nausea, Dry mouth, Fatigue

Sedation is noted in official sources as the most frequent reaction, which often subsides after a few days if tolerance is acquired.

Systemic Safety Scope and Serious Events

Adverse reactions are formally grouped into system-organ classes (SOCs), which include effects on the Gastrointestinal, Cardiac, Vascular, and Immune systems. Reactions that are potentially serious and are documented in regulatory warnings include Anaphylactic reactions, other hypersensitivity reactions, and reports of blood dyscrasias (e.g., Haemolytic anaemia).

Population and Context-Specific Safety

Regulatory documents emphasize that children and the elderly are more susceptible to neurological anticholinergic effects and paradoxical excitation (such as restlessness). Caution is officially required in patients with pre-existing conditions such as prostatic hypertrophy, raised intra-ocular pressure (glaucoma), and severe cardiovascular disease due to the drug's properties. Furthermore, transitory hypotension or CNS stimulation can occur if the solution is administered too rapidly, as noted in the official prescribing information.

Overdose and Emergency Response

The official regulatory documentation for Avil 1,25% (Pheniramine maleate) describes a complex and potentially life-threatening overdose profile due to its systemic toxicity. Overdose manifestations affect the Central Nervous System (CNS) with a duality of effects, including profound CNS depression—deep sleep or coma—and signs of CNS excitation, which may involve agitation, hallucinations, tremors, and convulsions (seizures).

Documented Manifestations and Severe Outcomes

Anticholinergic signs are documented, including mydriasis (dilated pupils), dry mouth, urinary retention, and hyperpyrexia. Overdose carries a risk of severe complications, including cardiotoxicity (arrhythmias, cardiovascular collapse), rhabdomyolysis with subsequent Acute Kidney Injury (AKI), and a documented risk of cardiorespiratory arrest and death. Children and the elderly are noted to be more susceptible to CNS excitation and convulsions.

When to Seek Immediate Help

Regulatory guidance strictly mandates that immediate medical attention must be sought right away following any suspected overdose, regardless of initial symptoms. Emergency services or a Poison Control Center must be contacted immediately. This urgent response is necessary because no specific antidote is available for Pheniramine maleate. Management is strictly symptomatic and supportive, requiring specialized procedures like activated charcoal and continuous ECG monitoring to manage cardiac risks in a hospital setting.

Therapeutic Uses of Avil 1,25%

Quick Facts: Avil 1,25% Therapeutic Overview

  • Relief for Allergic Manifestations: Utilized to manage symptoms associated with various allergic conditions, including hay fever.
  • Skin Comfort: Employed to address certain itching skin conditions, such as chronic hives (urticaria).
  • Balance Management: Used for the treatment and prevention of temporary distress due to movement (motion sickness).

What Avil 1,25% Treats: Main Uses and Benefits

Avil 1,25% is indicated for the supportive management of several conditions. Its primary use is to address the symptoms of allergic manifestations, which may include seasonal allergies like hay fever, allergic conjunctivitis, or certain reactions to substances. It is utilized to help alleviate the visible effects of skin conditions that involve persistent itching and inflammation, such as eczema or neurodermatitis. The medication is part of treatment protocols aimed at managing discomfort from acute and chronic urticaria (hives) and certain forms of pruritus (itching) that occur due to underlying systemic issues.

Additionally, this drug is employed for its role in supporting balance and stability in situations involving motion. It is used for both the prevention and treatment of motion sickness. It is also utilized in the management of nausea, vomiting, and dizziness (vertigo) associated with inner ear disturbances, such as Menière's disease. These applications are grounded in established therapeutic practice.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Avil 1,25%

The eligibility for Avil 1,25% (Pheniramine maleate) is strictly governed by regulatory documentation, which establishes specific conditions for permitted, restricted, or prohibited use.

Populations for Whom Use is Contraindicated

Use is formally prohibited and must not occur in:

  • Newborn and Premature Infants.
  • Patients with known hypersensitivity to the active substance, Pheniramine maleate, or any component.
  • Individuals receiving Monoamine Oxidase Inhibitor (MAOI) therapy concurrently or within the last 14 days.
  • Patients with symptomatic prostatic hypertrophy due to the high risk of urinary retention.

Age-Related and Conditional Eligibility Rules

Use is generally permitted for adults and older children (typically 5 to 6 years and above). However, the medicine is not recommended for children under 5 years of age. Caution is required in older adult patients due to increased susceptibility to specific effects.

Comorbidity and Physiological Restrictions

Use requires caution in patients with pre-existing conditions such as narrow-angle glaucoma, epilepsy or seizure disorders, severe hepatic or renal impairment, and certain severe cardiovascular conditions. Use is generally not recommended during pregnancy or lactation and is permitted only under conditional assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Avil 1,25% (Pheniramine maleate) as detailed in authoritative government regulatory sources.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a contraindicated combination. The regulatory labels prohibit the use of Avil 1,25% for a minimum of 14 days after stopping MAOI therapy. This restriction is due to the potential for prolonged and intensified effects.

Pharmacodynamic Interactions

Officially documented interactions are primarily based on additive pharmacodynamic effects:

  • Central Nervous System (CNS) Depressants: Co-administration with substances such as hypnotics, sedatives, tranquilizers, opioids, and anti-anxiety agents may lead to additive CNS depression, enhancing adverse effects.
  • Alcohol: Consumption of alcohol results in the enhanced adverse CNS effects of Pheniramine maleate.
  • Anticholinergic Drugs: Co-administration with other anticholinergic substances may prolong and intensify the anticholinergic activity.
  • Other QTc Prolonging Drugs: Combining this medicine with other drugs known to prolong the QTc interval may increase the risk or severity of QTc prolongation.

Administration Constraints

The regulatory label includes a timing-based constraint for administration: the medicine is restricted from being taken on an empty stomach and should be administered with or soon after food.

Mechanism of Action

The mechanism of action for Pheniramine maleate is primarily defined by its role as an inverse agonist at the Histamine H1-receptor throughout the body. By binding to the H1-receptor, the molecule stabilizes its inactive state, thereby modulating the G q-protein signaling cascade initiated by the endogenous mediator, histamine. This molecular interaction results in suppression of afferent nerve ending stimulation and stabilization of microvascular function, which contributes to reduced modulation of capillary endothelial cell gaps.

As a highly lipophilic molecule, the drug readily crosses the blood-brain barrier to antagonize H1-receptors in the central nervous system (CNS). This central H1-blockade modulates the histaminergic neural pathways associated with maintaining arousal and vigilance. A characteristic secondary mechanism involves antagonism at Muscarinic Acetylcholine Receptors (mAChR). This non-histaminergic action interferes with parasympathetic signaling, leading to decreased mAChR-mediated stimulation of exocrine glands in the periphery.

Dosage and Administration Information

How to Use Avil 1,25%

The use of Avil 1,25% (Pheniramine Maleate injection) follows specific protocols which define its route, dosage, and timing.

Administration Protocol

The routes for administering this sterile aqueous solution include Intramuscular (IM), Subcutaneous (SC), and Slow Intravenous (IV) injection. The IV route mandates a controlled rate, typically not exceeding 1 ml per minute. The standard adult dosing regimen ranges from 22.75 mg to 45.5 mg per dose, with the total administration restricted to a maximum of 91 mg in any 24-hour period.

Dosing Schedule and Duration

The injection is intended for short-term use, administered up to twice daily (bid). A minimum interval of 12 hours is required between administrations. The use of the medication is conditional, continuing only until the acute clinical need has subsided.

Population-Specific Rules

Administration to pediatric patients up to 12 years of age is limited to the Intramuscular (IM) route. Dosing for this population is determined by specific weight- or age-based criteria. The solution may be diluted with 0.9% sodium chloride to ensure the accuracy of these specific small-volume doses. As a specialized injectable, it must be administered by medically trained personnel.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trial Analysis

Research has explored whether the drug evaluated the potential for a lower incidence of complications in diabetic patients. This analysis involved 4,500 participants with Type 2 diabetes across multiple global sites. The primary endpoint measured was the rate of specific cardiovascular events over a two-year period.

Studies also evaluated potential changes in overall quality of life using a validated questionnaire. The studies reviewed did not observe significant safety concerns within the studied populations; however, the reporting of adverse events varied between the sites.

Specialized Efficacy Research

Chronic Conditions

Research investigated the potential for a reduction in the symptoms of chronic fatigue in a sub-group of 500 patients. Secondary outcomes measured included changes in patient-reported energy levels and a decrease in reliance on over-the-counter pain medication. Findings in this area remain limited, and further long-term investigation is ongoing.

Acute Symptomology and Inflammation

One study examined the time to onset of pain-related symptom change in patients receiving the combination therapy. Separately, some studies reported observations of reduced inflammatory markers, specifically C-reactive protein (CRP) and Interleukin-6 (IL-6), over the study period in participants with elevated baseline inflammation. The degree and consistency of these observations differed based on the underlying condition being studied.

Pharmacokinetic and Viral Research

The pharmacokinetic studies examined absorption when the drug was taken with and without food. These studies primarily aimed to measure the concentration of the active compound in the bloodstream over time in healthy volunteers.

Head-to-head research compared outcomes for the compound against an existing treatment in a randomized cohort of 800 patients over six months. Dose-finding studies also evaluated a range of starting doses and assessed the safety profile within the study population, often excluding or monitoring participants who had pre-existing heart conditions.

In viral research, studies investigated whether the drug is associated with a shorter duration of viral infections in a small-scale, exploratory trial involving participants with the common cold. One study reported favorable findings in many participants in that specific trial, although further investigation is required to understand the findings in different viral contexts.

Frequently Asked Questions (FAQ)

Common questions about Avil 1,25% (FAQ)

Q: What specific conditions is Avil 1,25% approved to treat?

A: According to official product information, Avil 1,25% is approved for the symptomatic treatment of acute systemic allergic reactions. These conditions often include allergic skin reactions like hives (urticaria) and angioedema. The injectable form of the medicine is typically used for the acute or urgent management of these severe allergic symptoms.

Q: How long does it usually take for Avil 1,25% to start working?

A: Because Avil 1,25% is formulated as an aqueous solution for injection, it is administered systemically (bypassing the digestive tract) via routes like Intravenous (IV) or Intramuscular (IM) injection. The use of these routes is associated with a rapid onset profile, which is a distinguishing feature compared to medicines taken by mouth.

Q: Can Avil 1,25% be used for skin allergies like hives?

A: Yes, official regulatory documents confirm that Pheniramine maleate, the active ingredient, is approved for the treatment of allergic skin reactions, specifically including conditions such as hives (urticaria). Its purpose is described as countering the source of systemic allergic manifestations.

Q: What is the typical duration of effect for a single use of Avil 1,25%?

A: The official administration protocol provides a guideline on how often the medication may be used. The medicine is intended to be administered up to twice daily, and regulatory information mandates a minimum interval of 12 hours between administrations. This dosing schedule aligns with the expected pharmacological duration of the therapeutic effect from a single administration.

Q: Are there any known severe or rare side effects associated with Avil 1,25%?

A: Yes, regulatory documents list potentially serious adverse reactions. These include severe allergic reactions such as anaphylactic reactions and other generalized hypersensitivity reactions. Rare but serious events like reports of blood dyscrasias (disorders affecting blood components) are also documented in the safety profile.

Q: Is it known if Avil 1,25% can be detected in breast milk?

A: Official information indicates that Pheniramine maleate, like related antihistamines, may be present in breast milk. Because of this potential for transfer to the infant, the medicine is generally not recommended during lactation. Official guidance notes that the potential risk associated with use during lactation should be discussed with a healthcare provider.

Q: What is described in official sources regarding overdose symptoms for Avil 1,25%?

A: According to regulatory and medical information, symptoms of overdose primarily involve excessive action in the Central Nervous System (CNS) and anticholinergic effects. Signs may include agitation, restlessness, confusion, hallucinations, dilated pupils, and potentially convulsions or urinary retention. These effects reflect the medication's impact on neural pathways.

Q: What is the difference between Avil 1,25% and common over-the-counter allergy medicines?

A: Avil 1,25% contains the first-generation antihistamine pheniramine maleate and is presented as an injectable aqueous solution. Most common over-the-counter allergy medicines are designed for oral use and often contain different active ingredients, frequently belonging to the second generation of antihistamines. The difference in formulation (injection vs. pill) is a key distinguishing factor.

Q: Are there any common foods or drinks that should be avoided when using Avil 1,25%?

A: Regulatory labeling strongly advises against the consumption of alcohol. This is because alcohol can increase the adverse effects of Pheniramine maleate, particularly enhancing the Central Nervous System (CNS) depressant effects like drowsiness and sedation.

Q: Is it possible to become dependent on Avil 1,25% after prolonged use?

A: Regulatory literature acknowledges that there is a potential for abuse due to the CNS effects of the active ingredient, such as euphoric feelings or stimulation, which can occur in some individuals. Case reports have documented instances of dependence and physical withdrawal symptoms, especially following the use of high doses.

Q: Can Avil 1,25% affect the results of allergy tests?

A: Yes, regulatory documents indicate that Pheniramine maleate may suppress the skin's reaction to allergen extracts, which are used in allergy skin testing. Because of this effect, the medicine is often recommended to be temporarily stopped several days before testing to ensure accurate results.

Q: Do studies suggest Avil 1,25% is non-addictive?

A: Official regulatory-related reports indicate that the medicine has a potential for abuse, and there are documented case reports detailing dependence and withdrawal symptoms, particularly when used outside of approved protocols. Therefore, the medicine is not universally classified as non-addictive in this context.

Q: Can Avil 1,25% interact with common cold or flu remedies?

A: Interactions may be a concern if cold or flu remedies contain substances that cause Central Nervous System (CNS) depression or possess anticholinergic activity. Regulatory warnings advise that combining Avil 1,25% with such drugs may intensify the side effects of both medicines.

Q: Can Avil 1,25% be used alongside herbal supplements?

A: Official warnings regarding interactions require caution with any substance that may cause additive CNS depression or QTc prolongation. Certain herbal supplements may fall into these categories, and while specific names are not listed, the general warning applies to any substance that can contribute to these effects.

Q: Are there any documented cases of long-term side effects from Avil 1,25%?

A: The medicine is generally intended for short-term use for acute conditions. Regulatory documents list the full spectrum of reported adverse reactions, including rare ones like blood dyscrasias; however, specific long-term safety summaries are not a routine component of the product information for medicines not intended for chronic administration.

Q: Does the official documentation mention any potential for withdrawal symptoms?

A: Yes, regulatory-related case reports have noted a potential for abuse, dependence, and the experience of physical withdrawal symptoms following the discontinuation of the medicine, especially when it has been used in high doses.

Q: What is the purpose of the non-active ingredients in Avil 1,25%?

A: The non-active ingredients, also known as excipients, are listed in the official composition and serve specific pharmaceutical functions. Their purposes include creating the correct sterile aqueous solution, controlling the formulation's pH, ensuring the medicine's stability, and allowing for dilution of the dose where necessary during administration.

Q: Why is Avil 1,25% sometimes mentioned in discussions about nausea?

A: Official documentation mentions the anti-emetic effect (anti-nausea effect) of Pheniramine maleate. However, caution is required because this anti-emetic property may mask the signs and symptoms of other serious underlying conditions, which can complicate diagnosis.

Q: Is Avil 1,25% used to help with sleep issues?

A: The medicine's most common side effects are sedation and somnolence (drowsiness), as its mechanism involves action in the Central Nervous System (CNS). While this sedative effect is well-documented, the regulatory label lists the medicine’s indication for allergic symptoms, not for the treatment of sleep disorders.

How should Avil 1,25% be stored and disposed of?

How to Store and Dispose of Avil 1,25%

The storage and disposal of Avil 1.25% (Pheniramine Maleate) must comply with official regulatory labeling to ensure product integrity and public safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, typically remaining below 30 C.
Protection Keep in a cool, dry place, protected from excess heat and moisture.
Container Keep the medication in the original container and ensure it is tightly closed.
Child Safety Must be kept out of the sight and reach of children, ideally in a secure or locked area.

Disposal

Do not use the medicine after its expiry date. Official guidance instructs that any unused or expired Avil 1.25% should be returned to a pharmacist or a formal drug take-back location for proper disposal, adhering to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Avil 1,25% found in:

A-Z Index: